

Pharmacy Updates and Changes

Coverage Change: Copaxone

Tufts Health Plan regularly reviews our prescription medication coverage in order to offer a pharmacy benefit that is clinically appropriate and cost effective. Effective **April 1, 2018**, we will no longer cover Copaxone® (glatiramer) on our formularies.

Covered Alternative

The generic for Copaxone®, **glatiramer**, is covered with a Tier 2 copayment

Drugs Moving to Non-Covered – Effective April 1, 2018

Effective April 1, 2018, we will no longer cover the following brands on our formularies.

Brand drugs moving to not covered	Covered lower tier alternative drug*	Tier of covered alternative
Amerge	naratriptan	Tier 1
Auryxia	calcium acetate	Tier 1
PhosLo		
Phoslyra		
Velphoro		
Axert	almotriptan	Tier 2
Cafergot	ergotamine/caffeine tablet	Tier 2
Cardura	doxazosin	Tier 1
Cardura XL	doxazosin	Tier 1
Doryx MPC	doxycycline	tier 1
Fenortho	ibuprofen	Tier 1
Fosrenol powder packets	lanthanum carbonate chewable tablets	Tier 2
Frova	frovatriptan	Tier 2
Imitrex	sumatriptan	Tier 1
Istalol 0.5% ophthalmic solution	timolol maleate 0.5%	Tier 2
Jalyn	dutasteride-tamsulosin capsule	Tier 1
Maxalt	rizatriptan	Tier 1
Maxalt-MLT	rizatriptan ODT tablet	Tier 1
Migranal nasal spray	sumatriptan nasal spray	Tier 1
Prudoxin	doxepin 5% cream	Tier 2
Relpax	eletriptan	Tier 2
Renagel	sevelamer carbonate tablets	Tier 2
Renvela		
Retin-A Micro 0.08% gel	tretinoin 0.025% gel	Tier 1
Sarafem	fluoxetine capsules	Tier 1
Strattera	atomoxetine	Tier 2
Tamiflu suspension	oseltamivir	Tier 2
Uroxatral	alfuzosin	Tier 1

Coverage Change to Help Address Opioid Crisis

Given the current state of the opioid crisis in our region and nationwide, Tufts Health Plan has decided to cover the life-saving drugs Narcan and Naloxone injection at a \$0 cost-share for all members.

We believe this is the right thing to do for our members and their families who are struggling with addiction. These drugs have saved thousands of lives, and we want to be sure our members have access to them without any cost barriers.

For our self-insured groups whom we administer their pharmacy benefit, we would like to provide a few important facts about this cost-share change:

1. It will have a very low financial impact, based on our data.
2. The cost of these drugs is low to begin with.
3. Other regional and national carriers are adopting \$0 cost-share strategies.

The opioid crisis is real, and we know you'll agree this is the right change to make for those in need.

For the most up to date pharmacy drug list and formularies, please visit tuftshealthplan.com.